| Literature DB >> 33316538 |
Teresa Schmid1, Julia Maier1, Melanie Martin1, Alpaslan Tasdogan2, Eugen Tausch3, Thomas F E Barth1, Stephan Stilgenbauer3, Johannes Bloehdorn3, Peter Möller4, Kevin Mellert1.
Abstract
The advent of highly effective treatments targeting the disease biology of chronic lymphocytic leukemia (CLL) has transformed the therapeutic field tremendously. However, transformation into an aggressive B-cell lymphoma, called Richter syndrome (RS), remains highly challenging since the treatment options for this condition are still insufficient. Exploratory drug testing and experimental studies are restricted by the lack of satisfactory models. We have established U-RT1, a cell line derived from a highly proliferating RS clonally related to the patient's underlying CLL. The cell line shows morphological features and an immunophenotype of RS-DLBCL (non-GCB). Molecular analysis revealed a complex karyotype with driver aberrations characteristic for RS such as loss of TP53 and CDKN2A. Furthermore, U-RT1 displays a chromosomal gain of the NOTCH1 gene locus and strong immunoreactivity for BCL-2. These features suggest that U-RT1 is the first eligible model system for investigations on the pathogenesis of RS and novel treatment options.Entities:
Keywords: CLL; DLBCL; In vitro model; Richter syndrome; Richter transformation
Year: 2020 PMID: 33316538 DOI: 10.1016/j.neo.2020.11.010
Source DB: PubMed Journal: Neoplasia ISSN: 1476-5586 Impact factor: 5.715